TY - JOUR T1 - Continuous positive airway pressure-treated patients' behaviours during the COVID-19 crisis JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00508-2020 VL - 6 IS - 4 SP - 00508-2020 AU - Jean-Louis Pépin AU - Odile Sauvaget AU - Jean Christian Borel AU - Christine Rolland AU - Marc Sapéne AU - Ines Amroussia AU - Sébastien Bailly AU - Renaud Tamisier Y1 - 2020/10/01 UR - http://openres.ersjournals.com/content/6/4/00508-2020.abstract N2 - Obstructive sleep apnoea (OSA) is one of the most prevalent chronic diseases, affecting nearly one billion people worldwide [1]. Continuous positive airway pressure (CPAP) is the first-line therapy for OSA [2], and is currently used by over one million people throughout France. A focus on the OSA population during the COVID-19 outbreak is of particular interest for the following two main reasons. 1) OSA is a multi-morbid disease with up to 70% of patients being obese [3] and exhibiting a high prevalence of cardiometabolic comorbidities. Such a clinical context is expected to be associated with a higher risk of severe forms of COVID-19 and a higher mortality rate [4]. 2) CPAP treatment is considered a high-risk aerosol-generating procedure potentially facilitating viral dispersion into the environment and transmission of infection [5–7].The #COVID19 pandemic has had limited impact on CPAP use by obstructive sleep apnoea patients. Mainly only those with suspected or proven COVID-19 stopped CPAP use, sometimes without a physician's advice, and were more likely to move to a separate bedroom. https://bit.ly/2RxQDZOWe thank Alison Foote (Grenoble Alpes University Hospital, Grenoble, France) for critically editing the manuscript. ER -